MPD: Measures involving haloperidol

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Crowley1:1	Crowley1	body weight	haloperidol	body weight [g] bw 39401 starting ending	inbred w/CC8	27	m	9-28wks	N=6	2012

Crowley1:3	Crowley1	drug and metabolite quantification	haloperidol	plasma haloperidol concentration [nM] haloperidol 39403 day: 30 60 90 120	inbred w/CC8	27	m	9-28wks	N=6	2012

Crowley1:7	Crowley1	inclined screen test	haloperidol	latency to move four paws, extrapyramidal side effects [s] latency 39407 day: 0 3 7 30 60 120	inbred w/CC8	27	m	9-28wks	N=6	2012

Crowley1:12	Crowley1	open field test	haloperidol	distance traveled, 60 min test [cm] horizontal_act 39412 day: 0 30 60 120	inbred w/CC8	27	m	9-28wks	N=6	2012

Crowley1:17	Crowley1	open field test	haloperidol	vertical activity, beam breaks, 60 min test [n] vertical_act 39417 day: 0 30 60 120	inbred w/CC8	27	m	9-28wks	N=6	2012

Crowley1:21	Crowley1	open field test	haloperidol	repetitive behavior, breaking of same beam, 60 min test [n] stereotypy 39421 day: 0 30 60 120	inbred w/CC8	27	m	9-28wks	N=6	2012

Crowley1:25	Crowley1	open field test	haloperidol	center occupancy, percentage of total time [%] pct_center 39425 day: 0 30 60 120	inbred w/CC8	27	m	9-28wks	N=6	2012

Crowley1:29	Crowley1	behavior observation	haloperidol	tongue protrusions, 15 min test [n] tongue 39429 day: 0 30 60 120	inbred w/CC8	27	m	9-28wks	N=6	2012

Crowley1:33	Crowley1	behavior observation	haloperidol	overt chewing movements, 15 min test [n] overtchew 39433 day: 0 30 60 120	inbred w/CC8	27	m	9-28wks	N=6	2012

Crowley1:37	Crowley1	behavior observation	haloperidol	subtle chewing movements, 15 min test [n] subtlechew 39437 day: 0 30 60 120	inbred w/CC8	27	m	9-28wks	N=6	2012

Crowley1:41	Crowley1	behavior observation	haloperidol	jaw tremor duration, 15 min test [s] jawtremor 39441 day: 0 30 60 120	inbred w/CC8	27	m	9-28wks	N=6	2012

Xenakis1:9	Xenakis1	body weight	haloperidol	body weight, treatment group [g] bw_Rx 111152 pre-treatment post-treatment	CC RIX	73	both	7-13wks	N=3	2020

Xenakis1:13	Xenakis1	inclined screen test	haloperidol	latency to move all four paws (extrapyramidal symptoms), treatment group [s] latency_Rx 111156 pre-treatment post-treatment	CC RIX	73	both	7-9wks	N=3	2020

Xenakis1:17	Xenakis1	open field test	haloperidol	distance traveled, 30 min test, treatment group [cm] distance_Rx 111160 pre-treatment post-treatment	CC RIX	73	both	7-13wks	N=3	2020

Xenakis1:21	Xenakis1	open field test	haloperidol	vertical activity (beam breaks), 30 min test, treatment group [n] vertical_Rx 111164 pre-treatment post-treatment	CC RIX	73	both	7-13wks	N=3	2020

Xenakis1:25	Xenakis1	open field test	haloperidol	time spent in center of arena, 30 min test, treatment group [s] center_Rx 111168 pre-treatment post-treatment	CC RIX	73	both	7-13wks	N=3	2020

Xenakis1:29	Xenakis1	open field test	haloperidol	stereotypy activity (beam breaks), 30 min test, treatment group [n] stereotypy_Rx 111172 pre-treatment post-treatment	CC RIX	73	both	7-13wks	N=3	2020

Xenakis1:31	Xenakis1	behavior observation	haloperidol	subtle vacuous chewing movements, 15 min test, treatment group, post-treatment [n] subtle_vcm_Rx_post 111174	CC RIX	73	both	11-13wks	N=5	2020

Xenakis1:32	Xenakis1	behavior observation	haloperidol	overt vacuous chewing movements, 15 min test, treatment group, post-treatment [n] overt_vcm_Rx_post 111175	CC RIX	73	both	11-13wks	N=5	2020

Xenakis1:33	Xenakis1	behavior observation	haloperidol	tongue protrusions, 15 min test, treatment group, post-treatment [n] tongue_Rx_post 111176	CC RIX	73	both	11-13wks	N=5	2020

Xenakis1:34	Xenakis1	behavior observation	haloperidol	jaw tremors, 15 min test, treatment group, post-treatment [n] jawtremor_Rx_post 111177	CC RIX	73	both	11-13wks	N=5	2020

Xenakis1:36	Xenakis1	drug and metabolite quantification	haloperidol	plasma haloperidol concentration, treatment group, post-treatment [ng/dL] haloperidol_conc_post 111179	CC RIX	53	both	11-13wks	N=2	2020

Crowley1

body weight

haloperidol

body weight [g] bw 39401 starting ending

inbred w/CC8

27

m

9-28wks

N=6

2012

Crowley1

drug and metabolite quantification

haloperidol

plasma haloperidol concentration [nM] haloperidol 39403 day: 30 60 90 120

inbred w/CC8

27

m

9-28wks

N=6

2012

Crowley1

inclined screen test

haloperidol

latency to move four paws, extrapyramidal side effects [s] latency 39407 day: 0 3 7 30 60 120

inbred w/CC8

27

m

9-28wks

N=6

2012

Crowley1

open field test

haloperidol

distance traveled, 60 min test [cm] horizontal_act 39412 day: 0 30 60 120

inbred w/CC8

27

m

9-28wks

N=6

2012

Crowley1

open field test

haloperidol

vertical activity, beam breaks, 60 min test [n] vertical_act 39417 day: 0 30 60 120

inbred w/CC8

27

m

9-28wks

N=6

2012

Crowley1

open field test

haloperidol

repetitive behavior, breaking of same beam, 60 min test [n] stereotypy 39421 day: 0 30 60 120

inbred w/CC8

27

m

9-28wks

N=6

2012

Crowley1

open field test

haloperidol

center occupancy, percentage of total time [%] pct_center 39425 day: 0 30 60 120

inbred w/CC8

27

m

9-28wks

N=6

2012

Crowley1

behavior observation

haloperidol

tongue protrusions, 15 min test [n] tongue 39429 day: 0 30 60 120

inbred w/CC8

27

m

9-28wks

N=6

2012

Crowley1

behavior observation

haloperidol

overt chewing movements, 15 min test [n] overtchew 39433 day: 0 30 60 120

inbred w/CC8

27

m

9-28wks

N=6

2012

Crowley1

behavior observation

haloperidol

subtle chewing movements, 15 min test [n] subtlechew 39437 day: 0 30 60 120

inbred w/CC8

27

m

9-28wks

N=6

2012

Crowley1

behavior observation

haloperidol

jaw tremor duration, 15 min test [s] jawtremor 39441 day: 0 30 60 120

inbred w/CC8

27

m

9-28wks

N=6

2012

Xenakis1

body weight

haloperidol

body weight, treatment group [g] bw_Rx 111152 pre-treatment post-treatment

CC RIX

73

both

7-13wks

N=3

2020

Xenakis1

inclined screen test

haloperidol

latency to move all four paws (extrapyramidal symptoms), treatment group [s] latency_Rx 111156 pre-treatment post-treatment

CC RIX

73

both

7-9wks

N=3

2020

Xenakis1

open field test

haloperidol

distance traveled, 30 min test, treatment group [cm] distance_Rx 111160 pre-treatment post-treatment

CC RIX

73

both

7-13wks

N=3

2020

Xenakis1

open field test

haloperidol

vertical activity (beam breaks), 30 min test, treatment group [n] vertical_Rx 111164 pre-treatment post-treatment

CC RIX

73

both

7-13wks

N=3

2020

Xenakis1

open field test

haloperidol

time spent in center of arena, 30 min test, treatment group [s] center_Rx 111168 pre-treatment post-treatment

CC RIX

73

both

7-13wks

N=3

2020

Xenakis1

open field test

haloperidol

stereotypy activity (beam breaks), 30 min test, treatment group [n] stereotypy_Rx 111172 pre-treatment post-treatment

CC RIX

73

both

7-13wks

N=3

2020

Xenakis1

behavior observation

haloperidol

subtle vacuous chewing movements, 15 min test, treatment group, post-treatment [n] subtle_vcm_Rx_post 111174

CC RIX

73

both

11-13wks

N=5

2020

Xenakis1

behavior observation

haloperidol

overt vacuous chewing movements, 15 min test, treatment group, post-treatment [n] overt_vcm_Rx_post 111175

CC RIX

73

both

11-13wks

N=5

2020

Xenakis1

behavior observation

haloperidol

tongue protrusions, 15 min test, treatment group, post-treatment [n] tongue_Rx_post 111176

CC RIX

73

both

11-13wks

N=5

2020

Xenakis1

behavior observation

haloperidol

jaw tremors, 15 min test, treatment group, post-treatment [n] jawtremor_Rx_post 111177

CC RIX

73

both

11-13wks

N=5

2020

Xenakis1

drug and metabolite quantification

haloperidol

plasma haloperidol concentration, treatment group, post-treatment [ng/dL] haloperidol_conc_post 111179

CC RIX

53

both

11-13wks

N=2

2020

Filter Table Results